Claims for Patent: 7,846,445

Summary for Patent: 7,846,445

Title:	Methods for production of unstructured recombinant polymers and uses thereof
Abstract:	The present invention provides methods of using unstructured recombinant polymers (URPs) and proteins containing one or more of the URPs. The present invention also provides microproteins, toxins and other related proteinaceous entities, as well as genetic packages displaying these entities, and the uses thereof. The present invention also provides recombinant polypeptides including vectors encoding the subject proteinaceous entities, as well as host cells comprising the vectors. The subject compositions have a variety of utilities including a range of pharmaceutical applications.
Inventor(s):	Schellenberger; Volker (Palo Alto, CA), Stemmer; Willem P. (Los Gatos, CA), Wang; Chia-wei (Santa Clara, CA), Scholle; Michael D. (Mountain View, CA), Popkov; Mikhail (San Diego, CA), Gordon; Nathaniel C. (Campbell, CA), Crameri; Andreas (Los Altos Hills, CA)
Assignee:	Amunix Operating, Inc. (Mountain View, CA)
Application Number:	11/715,296
Patent Claims:	1. A method of increasing serum secretion half-life of a protein, comprising: fusing an N- and/or C-terminus of said protein with at least one unstructured recombinant polypeptides (URPs) to create a monomeric fusion protein, wherein an individual URP comprises at least about 40 contiguous amino acids, and wherein (a) the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P) residues contained in the URP, constitutes at least 80% of the total amino acids of the URP, and the remainder, when present, consists of arginine or lysine, and the remainder does not contain methionine, cysteine, asparagine, and glutamine, wherein said UPR comprises at least three different types of amino acids selected from glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E) and proline (P); (b) at least 50% of the at least 40 contiguous amino acids in said URP are devoid of secondary structure as determined by Chou-Fasman algorithm; (c) wherein the URP has a Tepitope score less than -4; and wherein the monomeric fusion protein has at least a 2-fold increase in apparent molecular weight of the fusion protein as compared to the protein lacking said URP, wherein the apparent molecular weight is approximated by size exclusion chromatography, and wherein the fusion protein exhibits an increased half-life as compared to the protein lacking said URP. 2. The method of claim 1 wherein said fusing increases serum secretion half-life of the protein by at least 2-fold. 3. The method of claim 1, wherein glycine residues contained in the URP constitute at least 50% of the total amino acids of the URP. 4. The method of claim 1, wherein the sum of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P) residues contained in the URP, constitutes at least 90% of the total amino acids of the URP. 5. The method of claim 1, wherein one type of the amino acids selected from the group consisting of glycine (G), aspartate (D), alanine (A), serine (S), threonine (T), glutamate (E), and proline (P) constitutes at least 20% of the total amino acids of the URP. 6. The method of claim 1, wherein the URP comprises more than 100 contiguous amino acids. 7. The method of claim 1, wherein the therapeutic protein is selected from the group consisting of cytokines, growth factors, enzymes, receptors, microproteins, hormones, erythopoetin, adenosine deiminase, asparaginase, arginase, interferon, growth hormone, growth hormone releasing hormone, G-CSF, GM-CSM, insulin, hirudin, TNF-receptor, uricase, rasburicase, axokine, RNAse, DNAse, phosphatase, pseudomonas exotoxin, ricin, gelonin, desmoteplase, laronidase, thrombin, blood clotting enzyme, VEGF, protropin, somatropin, alteplase, interleukin, factor VII, factor VIII, factor X, factor IX, dornase, glucocerebrosidase, follitropin, glucagon, thyrotropin, nesiritide, alteplase, teriparatide, agalsidase, laronidase, and methioninase. 8. The method of claim 1, wherein the URP comprises more than 200 contiguous amino acids. 9. The method of claim 1, wherein the URP comprises more than 400 contiguous amino acids. 10. The method of claim 1, wherein one type of amino acid is no more than 30% of the total amino acids of the URP.

Details for Patent 7,846,445

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	06/23/1987		2025-09-27
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	10/16/1986		2025-09-27
Eli Lilly And Company	HUMATROPE	somatropin	For Injection	019640	02/04/1999		2025-09-27
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	10/08/1996		2025-09-27
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	08/29/2000		2025-09-27
Emd Serono, Inc.	SAIZEN	somatropin	For Injection	019764	01/16/2007		2025-09-27